Still's Disease Update Arthritis Research & Therapy has published an overarching review of Still's disease, claiming it is a single acquired, complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations, and https://t.co/8ctddvIq7k

Addressing PsA GRAPPA Domains With a JAKi Dr. Schwartzman and Dr. Ruderman discuss the importance of a domain-based approach in PsA management and consider the potential role of a JAK inhibitor. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/u5ThHz2sxo https://t.co/2itTzpCp3b

Simulation cost-effectiveness/QOL study compared Rx of psoriasis w/ biologics, phototherapy, or step-therapy Rx. Biologics had best QOL gains; step-therapy Rx similar w/ less variability & lower costs; phototherapy was cost-effective for payors. Pts had highest willingness to pay https://t.co/RyNooKhgQh

Gabapentinoid use 2008-2018: worldwide there was an annual incr of +17.2% (from 4.2/d to 18.3/d per 10K pop. Highest gaba use in high income countries, 6X higher than lower income (40/d vs 6.1/d) https://t.co/jXjxNj1Uyz https://t.co/bUhBpaPltc

Physician Use of Augmented Intelligence has Doubled A 2026 Physician Survey assessing AI and its use in Medical Practice has been published and follows earlier surveys on adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling https://t.co/4QoMR17Ure

Cross-sectional study from UK Clinical Practice Research Datalink Aurum looked at > 40K w/ #PMR Rx w/ steroids - 67% were coprescribed bisphosphonates (BP) & 79% Rx PPIs/H2RAs (less in males & pts deprived areas) resulting more Fx w/in 12 mos (2.32% vs 1.4%). https://t.co/b2DFJMjqCu

Retrospective study of 374 newly diagnosed microscopic polyangiitis (MPA) pts - 97 (26%) had severe infections w/in 6 mos - signif higher risk w/ high dose prednisone & chronic lung Dz. most common: bacterial (43%) & lung infx https://t.co/XXAxUZw7kx https://t.co/atK8Ob9zyQ

Leeds study of 63 pts w/ palindromic rheumatism (PR) progressed to Persistent IA (PIA) @ median 13.4 mos, hands predominating across flares. PIA developed in joints involved in PR flares in 71% of pts. @RA Dx, PR onset pts had signif higher swollen joints(4.1 vs 3.2) https://t.co/PnrQvWkUm4

Modest Benefits with AI Scribes on EHR Documentation Documenting patient visits in the EHR is essential to care, but a major contributor to clinician burnout. AI-enabled ambient documentation (“AI scribes”) can auto-generate draft clinical notes for clinician review. They may https://t.co/6HaUwpFYLC

Retrospective clinicopathologic review of 170 AORTIC surgical pathology cases (2009-16) - showed 87% w/ atherosclerosis, 13% aortitis/periaortitis and 2.4% atherosclerosis w/ excessive inflammation. Lymphoplasmacytic inflammation was most common w/ aortitis/periaortitis. https://t.co/CuP30dqRQU

152 pts w/ immune thrombocytopenia (ITP) Rx in DBRPCT of Ianalumab (9mg or 3 mg/kg) or PBO q mo x 4 mos (all on Eltrombopag). Time to Rx failure signif longer w/ ianalumab. Stable 6 month response better w/ 9-mg group vs PBO (62% vs 39%; P=0.045) https://t.co/J04trYAwLu https://t.co/Alm8V2SAXn

Litifilimab in Cutaneous Lupus Erythematosus Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting. https://t.co/3Wb6iFViOm